Energy balance is monitored by the hypothalamus. Malonyl-CoA, an intermediate in fatty acid synthesis, serves as an indicator of energy status in the hypothalamic neurons. The cellular malonyl-CoA level is determined by its rate of synthesis, catalyzed by acetyl-CoA carboxylase (ACC), and rate of removal, by fatty acid synthase (FAS). Malonyl-CoA functions in the hypothalamic neurons that express orexigenic and anorexigenic neuropeptides. Inhibitors of FAS, administered systemically or intracerebroventricularly to mice, increase hypothalamic malony-CoA and suppress food intake. Recent evidence suggests that the changes of hypothalamic malonyl-CoA during feeding and fasting cycles are caused by changes in the phosphorylation state and activity of ACC mediated via 5 0 -AMP-activated protein kinase (AMPK). Stereotactic delivery of a viral malonyl-CoA decarboxylase (MCD) vector into the ventral hypothalamus lowers malonyl-CoA and increases food intake. Fasting decreases hypothalamic malonyl-CoA and refeeding increases hypothalamic malonyl-CoA, to alter feeding behavior in the predicted manner. Malonyl-CoA level is under the control of AMP kinase which phosphorylates/inactivates ACC. Malonyl-CoA is an inhibitor of carnitine palmitoyl-CoA transferase-1 (CPT1), an outer mitochondrial membrane enzyme that regulates entry into, and oxidation of fatty acids, by mitochondria. CPT1c, a recently discovered, brain-specific enzyme expressed in the hypothalamus, has high sequence similarity to liver/muscle CPT1a/b and binds malonyl-CoA, but does not catalyze the prototypical reaction. This suggests that CPT1c has a unique function or activation mechanism. CPT1c knockout (KO) mice have lower food intake, weigh less and have less body fat, consistent with the role as an energy-sensing malonyl-CoA target. Paradoxically, CPT1c protects against the effects of a high-fat diet. CPT1cKO mice exhibit decreased rates of fatty acid oxidation, consistent with their increased susceptibility to diet-induced obesity. We suggest that CPT1c may be a downstream target of malonyl-CoA that regulates energy homeostasis.
Introduction
Seven years ago we and our colleagues at the Johns Hopkins Medical School discovered that inhibitors (cerulenin and C75) of fatty acid synthase (FAS) acting in the central nervous system suppressed food intake causing profound loss of body weight and adiposity. 1 The relevant site of action of these inhibitors is the domain that catalyzes the condensation of malonyl-CoA with the elongating fatty acyl chain. A blockade of this step would be expected to cause the build-up of the FAS substrate, malonyl-CoA. Our recent studies have validated this hypothesis.
Centrally acting FAS and ACC inhibitors alter food intake and energy expenditure
Food intake of both lean and obese (ob/ob, db/db and dietaryinduced obese/DIO) mice is rapidly (o2 h) suppressed after intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) injection of FAS inhibitors, C75 being the most extensively investigated inhibitor. FAS inhibitor-induced suppression of food intake correlates closely with increased hypothalamic [malonylCoA], 2 increased activation of neurons in the arcuate nucleus (Arc), 3 decreased expression of orexigenic (neuropeptide Y and agouti-related protein) and increased expression of anorexigenic (proopiomelanocortin and a-melanocyte-stimulating hormone) neuropeptides in the hypothalamus. 2, 4, 5 The responses of lean and obese (ob/ob, leptin-deficient or DIO) mice to repeated administration of FAS inhibitors differ. 6 C75 lowers food intake and adiposity of both lean and obese mice during the first few days of treatment. Lean mice, however, become resistant to the repetitive administration of FAS inhibitors after approximately 2 days and then exhibit no further reduction of food intake or body weight with food intake returning to pretreatment levels. Resistance to FAS inhibitors in obese mice occurs only after an extensive amount of body fat mass is reduced to that of lean controls. Weight loss provoked by FAS inhibitors is not due entirely to the suppression of food intake, but also to increased energy expenditure. Thus, centrally administered FAS inhibitors increase energy expenditure as measured by paired/isocaloric feeding, 6 indirect calorimetry 7 and increased fatty acid oxidation in skeletal muscle. 8, 9 Closely correlated with the increase in muscle fatty acid oxidation is the rapid (p2 h) phosphorylation/inactivation of acetyl-CoA carboxylase (ACC), causing reduced malonyl-CoA concentration. Lowering muscle malonyl-CoA, a potent inhibitor of muscle carnitine palmitoyl-CoA transferase-1b (CPT1b), releases CPT1b from inhibitory constraint facilitating the entry of fatty acids into mitochondria for b-oxidation. Correlated with these events are increases in the expression of skeletal muscle peroxisome proliferator-activated receptor (PPARa), a transcriptional activator of fatty acid oxidizing enzymes, and UCP3, a thermogenic mitochondrial uncoupling protein. 8, 9 Remarkably, central administration of an FAS inhibitor for 3 days leads to an increase in the number of mitochondria in white and red (soleus) skeletal muscle. 9 Both a-and b-adrenergic blockers prevent these effects. Thus, the sympathetic nervous system is implicated in the transmission of the 'malonyl-CoA signal' from brain to skeletal muscle. Consistent with the upregulation of uncoupling protein 3 and peroxisome proliferator-activated receptor-a is the concomitant increase in the expression of PPAR gamma coactivator 1-a, a transcriptional co-activator of the UCP3 and PPARa genes.
Physiological perturbation of hypothalamic [malonyl-CoA]
We developed a sensitive substrate 'recycling' assay that employs a bacterial malonyl-CoA decarboxylase (MCD), which possesses both malonyl-CoA and CoA transferase activity. With this multi-functional enzyme system it was possible to quantify the low concentrations of malonyl-CoA found in mouse hypothalamic tissue. 2 We showed that within 5-aminoimidazole-4-carboxamide ribonucleoside also activates the phosphorylation/inhibition of ACC and lowers malonyl-CoA concentration in a hypothalamic cell line in culture. 16 These findings have led to the speculation that during fasting the AMP/ATP ratio increases in neurons in the critical hypothalamic nuclei leading to the activation of AMPK, inactivation of ACC and a decrease in [malonyl-CoA].
Effect of a MCD vector on hypothalamic neurons in the ventral hypothalamus
An adenoviral-MCD expression vector (Ad-MCD) was used to lower [malonyl-CoA] both ex vivo in GT1-7 hypothalamic neurons and by bilateral stereotactic injection into the ventral hypothalamus in the region of the Arc. 16 The Ad-MCD vector harbors the mouse cDNA encoding a cytosolic MCD (cMCD) in which both the peroxisomal and mitochondrial targeting signals have been deleted to direct expression to the cytoplasm. As the region into which AdcMCD was to be delivered comprises only a small fraction of the entire hypothalamus, reliable quantification of the malonyl-CoA concentration within this limited region was not possible. Therefore, the Ad-cMCD vector was initially tested ex vivo with the GT1-7 hypothalamic neuronal cell line. The cellular level of cMCD was markedly increased in cells transduced with the vector and caused an approximately 80% decrease in [malonyl-CoA]. 16 These findings validated the approach to lower [malonyl-CoA] in hypothalamic neurons by accelerating its removal.
To verify the delivery of the Ad-cMCD vector to the ventral hypothalamus, a control adenoviral b-galactosidase expression vector (Ad-LacZ) was introduced into the ventral hypothalamus by bilateral stereotaxic injection. 16 b-galactosidase expression was detected in the ventral hypothalamus adjacent to and below the third ventricle and was particularly pronounced in the region encompassing the Arc, a region with neurons known to function in the regulation of feeding behavior. This verified the proper placement of the adenoviral expression vectors.
To lower [malonyl-CoA] in the region of the Arc, the AdcMCD vector was delivered into the ventral hypothalamus by bilateral stereotactic injection 16 after which food intake, body weight and the acute response to the FAS inhibitor, C75, were assessed. Following the introduction of the expression vector, food intake and body weight were increased over the next 12 days. 16 Furthermore, introduction of the Ad-cMCD vector into the ventral hypothalamus dramatically altered food intake in mice given an FAS inhibitor, C75, by i.c.v. injection. Thus, i.c.v. C75 completely suppressed food intake in control (Ad-LacZ) mice, whereas Ad-cMCD completely reversed the C75-induced blockade of food intake. 16 The fact that the anorexic effect of i.c.v. C75
was completely prevented, provides convincing support for the malonyl-CoA hypothesis. It should be noted that in other studies, 2 i.c.v. C75 caused a four-fold increase in hypothalamic malonyl-CoA. As Ad-cMCD was stereotactically delivered into the ventral hypothalamus, it is likely that the neurons targeted included those in the Arc, for example, neuropeptide Y/agouti-related protein and proopiomelanocortin/cocaine-and amphetamine-regulated transcript neurons, which function in the regulation of feeding behavior. More recently, these findings were verified by Rossetti's group, 17 who found that the stereotactic injection of an adeno-associated viral vector expressing MCD into the hypothalamus produced a large increase of food intake and obesity.
Genetic disruption of FAS gene expression in the hypothalamus increases [malonyl-CoA] and reduces body weight and adiposity Semenkovich et al. have crossed floxed FAS mice with RIP-Cre mice, Cre expression being driven by the rat insulin promoter. 18 In addition to driving expression in pancreatic b-cells, this promoter also activates expression in the hypothalamus. Although these mice exhibit no change in the regulation of insulin expression/secretion by pancreatic b-cells, they exhibit a phenotype (FAS 'knockdown') consistent with our finding that inhibition of hypothalamic FAS decreases food intake, body weight and adiposity. In collaboration with Clay Semenkovich and his colleagues (see Chakravarthy et al.
18
), we found that hypothalamic disruption of the FAS gene caused a X2-fold increase of hypothalamic [malonyl-CoA]. Thus, consistent with the regulatory role for hypothalamic malonyl-CoA in the regulation of body weight, mice with hypothalamic disruption of the FAS gene exhibit decreased adiposity (see Chakravarthy et al. 18 ).
Based on the evidence using multiple independent approaches to alter hypothalamic [malonyl-CoA], it is now clear that malonyl-CoA plays a key role in the regulation of feeding behavior and energy expenditure (also reviewed in Wolfgang and Lane 19 ).
Discovery of a brain-specific CPT1
Brain-specific CPT1c is a potential malonyl-CoA target enzyme that regulates energy homeostasis. The recent discovery of CPT1c as a brain-specific CPT1, 20 
Generation of the CPT1c KO mouse
Previously, we collaborated with investigators at Astellas Pharma Inc. to generate a CPT1c KO mouse. 21 The strategy employed was to utilize homologous recombination to replace exons 2 and 3 coding the translation initiation codon and first transmembrane domain. Intercrossing heterozygous animals resulted in the birth and weaning of homozygous CPT1c KO mice at the expected Mendelian ratio with no apparent developmental abnormalities. Using our CPT1c-specific antibodies, we have shown that CPT1c is absent in homozygous KO animals by western blot and immunohistochemistry. In addition, heterozygous mice exhibit half the expression of CPT1c as wild-type (WT) littermates and show phenotypic consequences (see below). These animals have now been backcrossed seven generations onto the BL/6 inbred strain.
CPT1c binds malonyl-CoA, but does not exhibit prototypical carnitine acyltransferase activity We have assayed acyl-CoA thioesters of varying chain length and saturation for their ability to catalyze acyl transfer to carnitine from more than 50 different acylCoAs. 19 We expressed the CPT1 isoforms in mammalian cells to more closely model their in vivo environment. However, we have not been able to detect transfer to carnitine in vitro from any acyl-CoA tested.
Localization of CPTs in the central nervous system
We have performed preliminary immunohistochemical studies to determine the localization and the neuron-/celltype in which CPT1a and CPT1c are expressed in the central nervous system. Recent experiments 22 indicate that CPT1c is highly expressed in the Arc and ventral medial nucleus and is clearly expressed in neurons and its expression does not overlap that of CPT1a suggesting that they may have different functions. In addition, areas of high expression include the hippocampus and amygdala. Clearly, CPT1c but not CPT1a is expressed in the appropriate area to act as a nutrient sensor.
CPT1c does not enhance the oxidation of long-chain fatty acids
The rate-limiting step in b-oxidation is the translocation of fatty acids from the cytosol into the mitochondrial matrix. The endpoint of mitochondrial fatty acids in most cells (ketones in hepatocytes) is the production of CO 2 . To determine whether a required activator may have been missed using the in vitro CPT1 assay system, the ability of CPT1c to support b-oxidation was tested by measuring the conversion of CPT1c KO mice are highly susceptible to the effects of a high-fat diet
CPT1c KO animals have a decreased food intake and lower body weight on rodent chow. We sought to determine if this decrease in food intake and body weight would be protective to weight gain on a high-fat diet. After approximately 15 weeks of age the mice were switched to diets in which either 10% (control) or 45% (high fat) of the calories were from fat. Male and female KO mice initially weighed less than their WT littermates. 19 Male and female KO animals on the control chow diet consistently weighed less than their WT littermates for the entire 14-week experiment. They also had an equivalent weight gain on the control diet. Unexpectedly, on the high-fat diet, both male and female KO mice began to rapidly gain weight. 19 Total body weight of the KO mice was lower at the beginning of the study (week 0), equivalent at week 5, and considerably greater than WT after 5 weeks. By 10-11 weeks body weights of the KO mice were higher than WT mice. Weight gain was significantly greater in both KO male and KO female mice. These results suggest that CPT1c is protective against a high-fat diet.
Using mice backcrossed to the BL/6 inbred mouse for seven generations, we have examined an even higher percentage of energy from fat diet (60%) in WT, heterozygous and KO mice. Again, KO mice gained significantly more weight than WT mice and heterozygous mice gained an intermediate amount of weight between WT and KO animals. This is a significant finding as heterozygous mice have half the expression of CPT1c as WT mice. Even in short-term (2 weeks) experiments, CPT1c KO mice gain significantly more weight than their WT counterparts.
Characterization of a second CPT1c KO mouse: CPT1c genetrap
We have now produced an independent line of mice with a null CPT1c allele utilizing a genetrap located in intron 6 (MJ Wolfgang and MD Lane, unpublished results). Genetraps in embryonic stem cells are used extensively to identify and knockout genes of interest in mice. Traps have value-added benefits to targeted knockouts due to the expression of reporter genes from endogenous loci. Promoterless retroviral vectors encoding a strong splice acceptor linked to a b-galactosidase reporter-neomycin resistance fusion gene (b-geo), are used to infect and screen embryonic stem cells for random insertion of the vector into a gene of interest. This generally creates a null allele due to the in-frame reading of b-geo and a stop codon. Baygenomics/UCSD provide the academic community with genetraps that include approximately 1/3 of the mouse genome. Among the collection of clones are several retroviral insertions into the cpt1c locus. We have obtained two lines of cpt1c-trapped ES cells. We have confirmed that the traps have integrated correctly and produce a CPT1c-LacZ fusion gene. Both clones are insertions into intron 6 of the cpt1c gene and prematurely truncate CPT1c following the two transmembrane regions that anchor CPT1c to the outer mitochondrial membrane, but before the catalytic core. We have generated germline transmitted trap mice and bred them to homozygosity. The trap generates a CPT1c null allele as assayed by western blot and northern blot. Interestingly, the heterozygotes have half of the expression of CPT1c (as was the case for the original KO) showing that CPT1c is expressed in a co-dominant fashion.
Concluding remarks
Malonyl-CoA plays a key role in the regulation of energy balance by the central nervous system. Levels of malonylCoA are determined by the complex interplay of enzymes (AMPK, ACC, MCD and FAS) that are responsive to nutrient availability. In the hypothalamus malonyl-CoA alters the expression of neuropeptides that regulate food intake and energy expenditure. Recent evidence has implicated CPT1c, a recently recognized brain-specific malonyl-CoA binding enzyme, as serving as an intermediary in this signaling pathway.
